Article Text

PDF
AB1462-HPR Risk factors for visual loss in giant cell arteritis: a retrospective study of 374 patients
  1. A. Zacharof1,
  2. T. Margaritis2,
  3. A. Kioumourtzis1,
  4. G. Galanis1,
  5. K. Kouninios1
  1. 11St Department of Internal Medicine
  2. 2Hellenic Red Cross, Athens, Greece

Abstract

Objectives To determine the risk factors—especially the effects of thrombocytosis—for permanent visual loss in patients with temporal arteritis.

Methods Three hundred seventy-four patients with temporal arteritis (all biopsy proven) were retrospectively studied for the development of permanent visual loss. We used multivariate logistic regression analysis to determine which of 17 pretreatment characteristics were associated with visual loss.

Results Visual ischemic manifestations occurred in 38 (10%) patients, including permanent visual loss in 13 (34%) patients. The independent predictors associated with an increased risk of permanent visual loss were a history of transient visual ischemic symptoms (odds ratio [OR] =6.3; 95% confidence interval [CI]: 1.4 to 29; P=0.02) and a higher platelet count (OR =3.7 per SD; 95% CI: 1.8 to 7.9; P=0.001). The presence of constitutional symptoms (OR =0.14; 95% CI: 0.02 to 0.77, P=0.01), polymyalgia rheumatica (OR =0.04; 95% CI: 0.01 to 0.48, P=0.02), and C-reactive protein level (OR =0.35 per SD; 95% CI: 0.13 to 0.92, P=0.03) were associated with a reduced risk. Upper limb artery involvement was excluded from the multivariate model, as no patients with that problem developed permanent visual loss. Of the 187 patients who presented with thrombocytosis (platelet count >400×109/L), 69 (37%) developed ischemic visual symptoms, compared with 34 (18%) of those without thrombocytosis.

Conclusions An elevated platelet count is a risk factor for permanent visual loss in temporal arteritis. The finding of thrombocytosis in a patient with suspected temporal arteritis should emphasize the need for urgent treatment, with consideration of using inhibitors of platelet aggregation or anticoagulation therapy.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.